Antifungal Susceptibilities of Candida Species Causing Vulvovaginitis and Epidemiology of Recurrent Cases
暂无分享,去创建一个
Sandra S. Richter | S. Richter | M. Pfaller | D. Diekema | R. Galask | S. Messer | R. Hollis | Michael A. Pfaller | Rudolph P. Galask | Shawn A. Messer | Richard J. Hollis | Daniel J. Diekema
[1] G. Quindós,et al. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. , 1999, The Journal of antimicrobial chemotherapy.
[2] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.
[3] M. Pfaller,et al. Activities of Fluconazole and Voriconazole against 1,586 Recent Clinical Isolates of Candida Species Determined by Broth Microdilution, Disk Diffusion, and Etest Methods: Report from The ARTEMIS Global Antifungal Susceptibility Program, 2001 , 2003, Journal of Clinical Microbiology.
[4] S. Zinner,et al. The Incidence of Genitourinary Infections in a Cohort of Healthy Women , 1994, Sexually transmitted diseases.
[5] P. Nyirjesy,et al. Chronic fungal vaginitis: the value of cultures. , 1995, American journal of obstetrics and gynecology.
[6] J. Sobel,et al. Vaginitis due to Candida krusei: epidemiology, clinical aspects, and therapy. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] M. Pfaller,et al. Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility , 2002, Journal of Clinical Microbiology.
[8] O. Lee,et al. Vulvovaginal carriage of yeasts other than Candida albicans , 2003, Sexually transmitted infections.
[9] J. Sobel,et al. Immunopathogenesis of recurrent vulvovaginal candidiasis , 1996, Clinical microbiology reviews.
[10] J. Sobel,et al. Comparative in vitro activity of antimycotic agents against pathogenic vaginal yeast isolates. , 1994, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.
[11] J. Sobel,et al. Symptomatic vulvovaginitis due to fluconazole-resistant Candida albicans in a female who was not infected with human immunodeficiency virus. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] K. Holmes,et al. Establishing the cause of genitourinary symptoms in women in a family practice. Comparison of clinical examination and comprehensive microbiology. , 1984, JAMA.
[13] R. Dietze,et al. Susceptibility profile of vaginal yeast isolates from Brazil , 2004, Mycopathologia.
[14] R. Barton,et al. An investigation into the pathogenesis of vulvo-vaginal candidosis , 2001, Sexually transmitted infections.
[15] L. Dorrell,et al. Vulvovaginitis due to fluconazole resistant Candida albicans following self treatment with non-prescribed triazoles , 2002, Sexually transmitted infections.
[16] P. Marone,et al. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. , 1997, American journal of obstetrics and gynecology.
[17] M. Pfaller,et al. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. , 2002, Diagnostic microbiology and infectious disease.
[18] L. Riley,et al. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] J. Sobel,et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. , 2004, The New England journal of medicine.
[20] M. Del Poeta,et al. Prevalence and antifungal susceptibility of vaginal yeasts in outpatients attending a gynecological center in Ancona, Italy , 1997, European Journal of Epidemiology.
[21] H. Nelis,et al. Prevalence of Vulvovaginal Candidiasis and Susceptibility to Fluconazole in Women , 2003 .
[22] Swate Te,et al. Boric acid treatment of vulvovaginal candidiasis. , 1974 .
[23] P. Nyirjesy,et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. , 1998, American journal of obstetrics and gynecology.
[24] M. Brandt,et al. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. , 1999, Diagnostic microbiology and infectious disease.
[25] J. Sobel,et al. Treatment of Torulopsis glabrata vaginitis: retrospective review of boric acid therapy. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] Jack D Sobel,et al. Treatment of vaginitis caused by Candida glabrata: use of topical boric acid and flucytosine. , 2003, American journal of obstetrics and gynecology.
[27] P. Nyirjesy,et al. Fluconazole Susceptibility of Vaginal Isolates Obtained from Women with Complicated Candida Vaginitis: Clinical Implications , 2003, Antimicrobial Agents and Chemotherapy.
[28] J. Rex,et al. Has antifungal susceptibility testing come of age? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[29] P. Nyirjesy,et al. Over‐the‐Counter and Alternative Medicines in the Treatment of Chronic Vaginal Symptoms , 1997, Obstetrics and gynecology.
[30] J. Sobel,et al. Vaginitis due to Saccharomyces cerevisiae: epidemiology, clinical aspects, and therapy. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.